Forte Biosciences (FBRX) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update
August 15, 2022 4:05 PM EDT-Forte Biosciences is Developing a Novel Pipeline for the Treatment of Autoimmune Diseases-
-Leadership Strengthened with Appointments of Hubert Chen, M.D. as Chief Scientific Officer and Stephen Doberstein, Ph.D. to the Board of Directors-
-Ended second quarter 2022 with approximately $38.5 million in cash and cash equivalents-
DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc.... More
